Suzanne Louise Topalian filed a Form 3 Initial Statement of Beneficial Ownership with the SEC on October 28, 2026, disclosing her status as a newly reporting director of Vir Biotechnology, Inc. (NASDAQ:VIR) as of an event date of October 27, 2026.

Key Highlights

  • Reporting Person: Suzanne Louise Topalian, identified as a Director of Vir Biotechnology, Inc.
  • Event Date: The date of the event requiring the statement is listed as October 27, 2026.
  • Common Stock Held: Topalian reported 0 shares of common stock beneficially owned directly.
  • Derivative Securities: No derivative securities, including options, warrants, or convertible securities, were reported in Table II.
  • Filing Type: Filed by one reporting person, with the form signed by Vanina de Verneuil as Attorney-In-Fact on October 28, 2026.

Topalian's Initial Beneficial Ownership Disclosure at Vir Biotechnology

According to the filing, Suzanne Louise Topalian submitted her initial statement of beneficial ownership in connection with her role as a Director at Vir Biotechnology, Inc., whose common stock trades on NASDAQ under the symbol VIR. The filing was made pursuant to Section 16(a) of the Securities Exchange Act of 1934, which requires officers, directors, and certain shareholders to disclose their initial securities holdings upon becoming a reporting person.

The filing discloses that Topalian directly holds 0 shares of Vir Biotechnology common stock as of the event date of October 27, 2026. No indirect beneficial ownership was reported in Table I, and Table II, which covers derivative securities such as puts, calls, warrants, options, and convertible securities, contains no entries. The address listed for the reporting person is c/o Vir Biotechnology, Inc., 1800 Owens Street, Suite 900, San Francisco, California 94158. The form was signed on October 28, 2026, by Vanina de Verneuil, Attorney-In-Fact.

The filing is designated as an individual filing, meaning it was submitted by one reporting person and not on a joint or group basis. No amendments to a prior Form 3 are indicated, as no original filing date is listed in the amendment field.

What Was Disclosed

Topalian filed a Form 3 as a newly reporting director of Vir Biotechnology, Inc., disclosing zero shares of common stock held directly and no derivative securities, with an event date of October 27, 2026.